Chugai Pharmaceutical Co.... (CHGCY)
29.67
0.79 (2.74%)
At close: Apr 21, 2025, 3:59 PM
2.74% (1D)
| Bid | 29.6 |
| Market Cap | 97.65B |
| Revenue (ttm) | 1,084.6B |
| Net Income (ttm) | 355.04B |
| EPS (ttm) | 0.82 |
| PE Ratio (ttm) | 36.18 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 29.73 |
| Volume | 23,139 |
| Avg. Volume (20D) | 215,914 |
| Open | 21.73 |
| Previous Close | 28.88 |
| Day's Range | 29.11 - 29.97 |
| 52-Week Range | 14.52 - 30.37 |
| Beta | 0.70 |
About CHGCY
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and ne...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Aug 3, 2012
Employees 5,026
Stock Exchange PNK
Ticker Symbol CHGCY
Website https://www.chugai-pharm.co.jp
2 months ago · seekingalpha.com
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q4 2024 Earnings Call TranscriptChugai Pharmaceutical Co., Ltd. (OTCPK:CHGCF) Q4 2024 Earnings Conference Call January 30, 2025 3:30 AM ET Company Participants Kae Miyata - Head of Corporate Communications Department Osamu Okuda - R...